What’s notable about ITMN’s pursuit of ritonavir boosting is that the impetus has more to do with dose size than with dosing frequency (the rationale for using ritonavir with HIV protease inhibitors). By allowing a smaller dose to have the same efficacy, ritonavir facilitates co-formulation of ITMN-191 with other oral agents into an Atripla-like pill.
p.s. Would you be kind enough to update the ITMN ReadMeFirst? T.i.a.
Market Data 
Markets 
AI
